Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case

All NewsJune 5, 2025

The Federal Circuit upheld a ruling that Moderna’s COVID-19 vaccine does not infringe Alnylam’s mRNA patents related to the SM-102 lipid used in Spikevax.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent